suxamethonium 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
quaternary ammonium compounds 2489 306-40-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • suxamethonium chloride
  • succinylcholine
  • suxamethonium
  • dicholine succinate
  • succinic acid dicholine diester
  • succinocholine
  • succinoylcholine
  • succinylbischoline
  • succinylcholine chloride
A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.
  • Molecular weight: 290.40
  • Formula: C14H30N2O4
  • CLOGP: -6.87
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 52.60
  • ALOGS: -5.68
  • ROTB: 11

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Aug. 20, 1952 FDA SANDOZ

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 580.78 41.29 162 4405 23471 63460984
Hyperthermia malignant 194.50 41.29 36 4531 798 63483657
Cardiac arrest 192.34 41.29 105 4462 92440 63392015
Hypotension 189.20 41.29 156 4411 272448 63212007
Exposure during pregnancy 177.21 41.29 120 4447 155427 63329028
Diabetes insipidus 158.62 41.29 37 4530 2588 63481867
Anaphylactic reaction 131.65 41.29 73 4494 66027 63418428
Renal ischaemia 126.53 41.29 24 4543 609 63483846
PCO2 increased 121.73 41.29 26 4541 1213 63483242
Bronchospasm 121.57 41.29 46 4521 17234 63467221
Maternal exposure during pregnancy 108.47 41.29 104 4463 219958 63264497
PO2 increased 101.03 41.29 21 4546 858 63483597
Foetal death 98.61 41.29 35 4532 10945 63473510
Blood pH decreased 97.76 41.29 25 4542 2562 63481893
Neuromuscular block prolonged 92.50 41.29 18 4549 524 63483931
Oxygen saturation abnormal 90.07 41.29 25 4542 3504 63480951
Blood bicarbonate decreased 89.83 41.29 24 4543 2917 63481538
Ventricular tachycardia 88.03 41.29 38 4529 19941 63464514
Rhabdomyolysis 85.95 41.29 48 4519 43903 63440552
Left ventricular dysfunction 84.61 41.29 32 4535 11956 63472499
Apnoea 81.36 41.29 28 4539 7994 63476461
Delayed recovery from anaesthesia 80.42 41.29 17 4550 754 63483701
Foetal exposure during pregnancy 79.59 41.29 41 4526 31921 63452534
Bradycardia 72.57 41.29 52 4515 73175 63411280
Premature baby 70.79 41.29 33 4534 20702 63463753
Seizure 67.68 41.29 64 4503 132570 63351885
Status epilepticus 67.18 41.29 29 4538 15204 63469251
Electroencephalogram abnormal 62.54 41.29 19 4548 3653 63480802
Hyperkalaemia 59.52 41.29 41 4526 54162 63430293
Maternal exposure during delivery 59.15 41.29 15 4552 1485 63482970
Premature delivery 58.98 41.29 33 4534 30248 63454207
Tracheal deviation 57.57 41.29 10 4557 152 63484303
Phrenic nerve paralysis 55.67 41.29 10 4557 186 63484269
Renal impairment 55.60 41.29 48 4519 88307 63396148
Blood magnesium decreased 54.53 41.29 24 4543 13174 63471281
Drug interaction 52.47 41.29 73 4494 229058 63255397
Patent ductus arteriosus 51.65 41.29 17 4550 4233 63480222
Anaesthetic complication 50.54 41.29 14 4553 1946 63482509
Clonus 50.20 41.29 17 4550 4619 63479836
Kounis syndrome 47.58 41.29 13 4554 1717 63482738
Encephalopathy 46.65 41.29 31 4536 38589 63445866
Premature labour 42.97 41.29 20 4547 12484 63471971
Pulseless electrical activity 42.18 41.29 17 4550 7504 63476951
Pseudocholinesterase deficiency 42.07 41.29 7 4560 81 63484374
Myoclonic epilepsy 41.94 41.29 11 4556 1243 63483212

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperthermia malignant 393.48 34.12 80 3424 2097 34951330
Anaphylactic shock 300.07 34.12 96 3408 15845 34937582
Cardiac arrest 166.45 34.12 109 3395 96050 34857377
Serotonin syndrome 139.81 34.12 58 3446 19875 34933552
Anaphylactic reaction 118.87 34.12 60 3444 32241 34921186
Neuromuscular block prolonged 82.11 34.12 17 3487 484 34952943
Electrocardiogram ST segment elevation 80.01 34.12 27 3477 5211 34948216
Rhabdomyolysis 79.79 34.12 61 3443 68102 34885325
Hypotension 79.71 34.12 104 3400 221545 34731882
Procedural hypotension 66.35 34.12 16 3488 920 34952507
Anaesthetic complication 63.50 34.12 16 3488 1104 34952323
Drug interaction 60.30 34.12 92 3412 225854 34727573
Seizure like phenomena 59.02 34.12 14 3490 750 34952677
Bradycardia 58.07 34.12 53 3451 75365 34878062
Pseudocholinesterase deficiency 55.94 34.12 8 3496 19 34953408
Respiratory acidosis 54.09 34.12 20 3484 5030 34948397
Bronchospasm 51.67 34.12 24 3480 10707 34942720
Metabolic acidosis 50.84 34.12 39 3465 43641 34909786
Apnoea 48.71 34.12 20 3484 6644 34946783
Muscle rigidity 45.96 34.12 22 3482 10496 34942931
Ventricular tachycardia 45.41 34.12 30 3474 26549 34926878
Stress cardiomyopathy 41.09 34.12 13 3491 2046 34951381
Tachycardia 40.39 34.12 46 3458 84726 34868701
Pseudomonal sepsis 37.81 34.12 14 3490 3533 34949894
Neuromuscular blockade 37.61 34.12 8 3496 260 34953167
Blood creatine phosphokinase increased 35.40 34.12 32 3472 44825 34908602
Hypoxia 35.28 34.12 35 3469 55060 34898367
Pulseless electrical activity 34.31 34.12 16 3488 7195 34946232

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic shock 861.14 30.19 259 7566 35737 79700826
Hyperthermia malignant 545.72 30.19 110 7715 2807 79733756
Cardiac arrest 328.47 30.19 206 7619 171890 79564673
Anaphylactic reaction 246.50 30.19 133 7692 83610 79652953
Hypotension 240.21 30.19 253 7572 440064 79296499
Neuromuscular block prolonged 169.83 30.19 35 7790 995 79735568
Bronchospasm 164.35 30.19 69 7756 24790 79711773
Exposure during pregnancy 146.13 30.19 102 7723 101030 79635533
Rhabdomyolysis 144.33 30.19 102 7723 103029 79633534
Ventricular tachycardia 127.11 30.19 68 7757 41867 79694696
Bradycardia 125.78 30.19 105 7720 135452 79601111
Serotonin syndrome 125.32 30.19 69 7756 44958 79691605
Diabetes insipidus 121.84 30.19 37 7788 5200 79731363
PCO2 increased 118.53 30.19 29 7796 1811 79734752
Maternal exposure during pregnancy 110.87 30.19 98 7727 136440 79600123
Anaesthetic complication 110.50 30.19 30 7795 2829 79733734
Renal ischaemia 109.91 30.19 25 7800 1137 79735426
Apnoea 103.26 30.19 40 7785 11664 79724899
Pseudocholinesterase deficiency 101.19 30.19 17 7808 149 79736414
Foetal death 98.58 30.19 35 7790 8009 79728554
Delayed recovery from anaesthesia 95.84 30.19 24 7801 1649 79734914
Drug interaction 95.05 30.19 156 7669 415027 79321536
Blood pH decreased 87.42 30.19 28 7797 4683 79731880
PO2 increased 87.09 30.19 22 7803 1566 79734997
Oxygen saturation abnormal 79.99 30.19 26 7799 4556 79732007
Electrocardiogram ST segment elevation 78.72 30.19 30 7795 8367 79728196
Left ventricular dysfunction 71.88 30.19 36 7789 19325 79717238
Diarrhoea 70.55 30.19 4 7821 880485 78856078
Blood bicarbonate decreased 69.01 30.19 24 7801 5167 79731396
Procedural hypotension 67.89 30.19 19 7806 2004 79734559
Tachycardia 67.35 30.19 85 7740 177683 79558880
Pulseless electrical activity 66.70 30.19 31 7794 14129 79722434
Neuromuscular blockade 63.14 30.19 14 7811 566 79735997
Hyperkalaemia 58.81 30.19 64 7761 114334 79622229
Fatigue 57.38 30.19 11 7814 929716 78806847
Hypoxia 57.02 30.19 60 7765 103183 79633380
Electroencephalogram abnormal 56.70 30.19 21 7804 5413 79731150
Cardio-respiratory arrest 56.29 30.19 61 7764 108449 79628114
Maternal exposure during delivery 56.13 30.19 15 7810 1331 79735232
Respiratory acidosis 54.25 30.19 25 7800 11175 79725388
Muscle rigidity 53.99 30.19 30 7795 19852 79716711
Tracheal deviation 53.36 30.19 10 7815 171 79736392
Seizure 52.87 30.19 78 7747 188756 79547807
Ventricular fibrillation 52.67 30.19 35 7790 31891 79704672
Status epilepticus 52.65 30.19 32 7793 25009 79711554
Therapeutic product effect prolonged 52.30 30.19 12 7813 567 79735996
Clonus 52.01 30.19 21 7804 6819 79729744
Premature delivery 49.37 30.19 30 7795 23437 79713126
Phrenic nerve paralysis 47.04 30.19 10 7815 331 79736232
Seizure like phenomena 46.90 30.19 14 7811 1853 79734710
Nausea 46.56 30.19 18 7807 957178 78779385
Stress cardiomyopathy 45.12 30.19 22 7803 11144 79725419
Unresponsive to stimuli 45.10 30.19 40 7785 55748 79680815
Blood magnesium decreased 45.06 30.19 25 7800 16487 79720076
Premature labour 44.65 30.19 20 7805 8370 79728193
Post procedural complication 43.90 30.19 28 7797 23801 79712762
Anaphylactoid shock 43.72 30.19 11 7814 770 79735793
Fear 43.42 30.19 27 7798 21959 79714604
Metabolic acidosis 42.09 30.19 46 7779 82483 79654080
Allergy test negative 41.58 30.19 9 7816 325 79736238
Anaesthetic complication neurological 40.71 30.19 10 7815 634 79735929
Drug ineffective 40.21 30.19 210 7615 1080703 78655860
Haemodynamic instability 38.57 30.19 23 7802 17359 79719204
Symptom masked 37.44 30.19 11 7814 1379 79735184
Muscle contractions involuntary 37.27 30.19 14 7811 3751 79732812
Anhedonia 36.45 30.19 21 7804 14877 79721686
Trismus 35.51 30.19 15 7810 5452 79731111
Methaemoglobinaemia 35.28 30.19 15 7810 5542 79731021
Normal newborn 34.92 30.19 16 7809 7056 79729507
Arthralgia 34.69 30.19 7 7818 571796 79164767
Renal impairment 34.20 30.19 58 7767 157725 79578838
Airway complication of anaesthesia 34.19 30.19 8 7817 412 79736151
Headache 33.94 30.19 11 7814 653761 79082802
Hypotonia 33.79 30.19 19 7806 12851 79723712
Myoclonic epilepsy 33.66 30.19 11 7814 1959 79734604
Paralysis 33.38 30.19 19 7806 13158 79723405
Kounis syndrome 32.05 30.19 13 7812 4269 79732294
CSWS syndrome 32.03 30.19 5 7820 26 79736537
Encephalopathy 31.67 30.19 36 7789 67361 79669202
Hypercapnia 31.36 30.19 16 7809 8919 79727644
Tryptase increased 30.69 30.19 8 7817 645 79735918
Vasoplegia syndrome 30.57 30.19 12 7813 3618 79732945

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M03AB01 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
Choline derivatives
MeSH PA D009465 Neuromuscular Agents
MeSH PA D009466 Neuromuscular Blocking Agents
MeSH PA D009467 Neuromuscular Depolarizing Agents
MeSH PA D018373 Peripheral Nervous System Agents
FDA EPC N0000175719 Depolarizing Neuromuscular Blocker
FDA PE N0000175733 Neuromuscular Depolarizing Blockade
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:88188 allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Muscle relaxation, function indication 11977004
General anesthesia indication 50697003
Skeletal Muscle Relaxation for Endotracheal Intubation indication
Ocular hypertension contraindication 4210003 DOID:9282
Hypocalcemia contraindication 5291005
Poisoning by digitalis glycoside contraindication 12876009
Hyperkalemia contraindication 14140009
Glaucoma contraindication 23986001 DOID:1686
Infectious disease contraindication 40733004
Myxedema contraindication 43153006 DOID:11634
Hypokalemia contraindication 43339004
Burn injury contraindication 48333001
Bradycardia contraindication 48867003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Muscular dystrophy contraindication 73297009 DOID:9884
Duchenne muscular dystrophy contraindication 76670001 DOID:11723
Third degree burn injury contraindication 80247002
Spinal cord injury contraindication 90584004
Myasthenia gravis contraindication 91637004 DOID:437
Fracture of bone contraindication 125605004
Disorder of muscle contraindication 129565002 DOID:423
Spasticity contraindication 221360009
Rhabdomyolysis contraindication 240131006
Anemia contraindication 271737000 DOID:2355
Injury of eye region contraindication 282752000
Deficiency of cholinesterase contraindication 360607009
At risk for aspiration contraindication 371736008
Primary malignant neoplasm contraindication 372087000
Surgical procedure on eye proper contraindication 373353005
Fever contraindication 386661006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Malignant hyperthermia contraindication 405501007
Cardiac arrest contraindication 410429000 DOID:0060319
Traumatic injury contraindication 417746004
Cardiac Decompensation contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscle-type nicotinic acetylcholine receptor Ion channel AGONIST CHEMBL CHEMBL
Acetylcholinesterase Enzyme Ki 4.68 CHEMBL

External reference:

IDSource
4017730 VUID
N0000178917 NUI
D00766 KEGG_DRUG
71-27-2 SECONDARY_CAS_RN
4017730 VANDF
4019935 VANDF
C0038627 UMLSCUI
CHEBI:45652 CHEBI
SCK PDB_CHEM_ID
CHEMBL703 ChEMBL_ID
CHEMBL983 ChEMBL_ID
DB00202 DRUGBANK_ID
5314 PUBCHEM_CID
4004 IUPHAR_LIGAND_ID
10154 RXNORM
1940 MMSL
5517 MMSL
d00376 MMSL
001676 NDDF
005590 NDDF
372724004 SNOMEDCT_US
3822002 SNOMEDCT_US
58907007 SNOMEDCT_US
D013390 MESH_DESCRIPTOR_UI
26 INN_ID
J2R869A8YF UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 0404-9960 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 13 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9983 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 19 sections
SUCCINYLCHOLINE CHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0404-9983 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 19 sections
QUELICIN Human prescription drug label 1 0409-6629 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 29 sections
QUELICIN Human prescription drug label 1 0409-6629 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 29 sections
QUELICIN Human prescription drug label 1 0409-6629 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 29 sections
QUELICIN Human prescription drug label 1 0409-6629 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 29 sections
QUELICIN Human prescription drug label 1 0409-6629 INJECTION, SOLUTION 20 mg INTRAMUSCULAR NDA 29 sections
QUELICIN Human prescription drug label 1 0409-6970 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 29 sections
QUELICIN Human prescription drug label 1 0409-6970 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 29 sections
QUELICIN Human prescription drug label 1 0409-6970 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 29 sections
QUELICIN Human prescription drug label 1 0409-6970 INJECTION, SOLUTION 100 mg INTRAMUSCULAR NDA 29 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3009 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 23 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3411 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 20 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3411 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 20 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-3411 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 20 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-9053 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 20 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-9053 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 20 sections
Anectine HUMAN PRESCRIPTION DRUG LABEL 1 0781-9053 INJECTION, SOLUTION 20 mg INTRAVENOUS NDA 20 sections
Succinylcholine Chloride Human Prescription Drug Label 1 14445-407 INJECTION 20 mg INTRAVENOUS ANDA 22 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 14789-104 INJECTION 20 mg INTRAVENOUS ANDA 21 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 14789-104 INJECTION 20 mg INTRAVENOUS ANDA 21 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 14789-104 INJECTION 20 mg INTRAVENOUS ANDA 21 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-493 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 26 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-493 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 26 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-677 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 31 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 25021-677 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 31 sections
Succinylcholine Chloride Human Prescription Drug Label 1 31722-981 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 30 sections
Succinylcholine Chloride Human Prescription Drug Label 1 31722-981 INJECTION, SOLUTION 20 mg INTRAVENOUS ANDA 30 sections
Succinylcholine Chloride HUMAN PRESCRIPTION DRUG LABEL 1 42571-371 INJECTION 200 mg INTRAMUSCULAR ANDA 24 sections